XKRX205470
Market cap165mUSD
Jan 06, Last price
1,986.00KRW
1D
16.69%
1Q
28.46%
IPO
317.01%
Name
Humasis Co Ltd
Chart & Performance
P/E
—
P/S
17.50
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.05%
Rev. gr., 5y
7.44%
Revenues
13.83b
-97.07%
Net income
-55.42b
L
CFO
-55.48b
L
Dividend
Dec 28, 2022800 KRW/sh
Profile
Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 13,827,304 -97.07% | 471,272,761 46.44% | |||||||
Cost of revenue | 59,909,681 | 243,288,162 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (46,082,377) | 227,984,599 | |||||||
NOPBT Margin | 48.38% | ||||||||
Operating Taxes | (6,755,775) | 54,930,783 | |||||||
Tax Rate | 24.09% | ||||||||
NOPAT | (39,326,603) | 173,053,816 | |||||||
Net income | (55,424,406) -130.35% | 182,626,628 20.78% | |||||||
Dividends | (6,838,822) | ||||||||
Dividend yield | 1.47% | ||||||||
Proceeds from repurchase of equity | (5,140,702) | 662,322 | |||||||
BB yield | 2.14% | -0.14% | |||||||
| Debt | |||||||||
Debt current | 92,586 | 747,912 | |||||||
Long-term debt | 326,144 | 4,198,424 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 101,333 | 518,037 | |||||||
Net debt | (254,458,582) | (317,851,825) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (55,482,655) | 202,596,059 | |||||||
CAPEX | (22,203,679) | (44,634,234) | |||||||
Cash from investing activities | 54,145,523 | (322,678,972) | |||||||
Cash from financing activities | (5,929,363) | (37,393,027) | |||||||
FCF | (18,065,374) | 138,239,092 | |||||||
| Balance | |||||||||
Cash | 242,990,880 | 318,694,614 | |||||||
Long term investments | 11,886,432 | 4,103,547 | |||||||
Excess cash | 254,185,947 | 299,234,523 | |||||||
Stockholders' equity | 292,863,562 | 338,635,987 | |||||||
Invested Capital | 33,451,285 | 4,199,739 | |||||||
ROIC | |||||||||
ROCE | 75.13% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 127,280 | 130,935 | |||||||
Price | 1,886.00 -47.06% | 3,562.50 -14.67% | |||||||
Market cap | 240,050,906 -48.54% | 466,455,168 -18.32% | |||||||
EV | (14,407,676) | 148,603,343 | |||||||
EBITDA | (41,359,126) | 232,831,382 | |||||||
EV/EBITDA | 0.35 | 0.64 | |||||||
Interest | 67,856 | 93,951 | |||||||
Interest/NOPBT | 0.04% | ||||||||